Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-Hodgkin lymphoma using Efungumab and amphotericin B colloid dispersion.

Abstract

Invasive fungal infections are serious complications of cancer therapy. We present a case report of a 12-year-old boy diagnosed with abdominal non-Hodgkin lymphoma and fecal and Candida peritonitis during induction chemotherapy. The invasive mycosis was managed using a combined approach of systemic antifungal agents including efungumab and surgical interventions. Efungumab, a recombinant antibody that inhibits extracellular heat shock protein 90, was used in combination with amphotericin B colloid dispersion after the failure of standard approaches.

• Authors: Zdenka Krenova, Zdenek Pavelka, Petr Lokaj, Jarmila Skotakova, Ivana Kocmanova, Otakar Teyschl, Leos Kren, Peter Mudry, Jaroslav Sterba
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 32 Issue 2 Pg. 128-30 (Mar 2010) ISSN: 1536-3678 [Electronic] United States
• PMID: 20098335 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antifungal Agents
• HSP90 Heat-Shock Proteins
• Amphotericin B
• efungumab

Topics

• Abdominal Neoplasms (complications, drug therapy)
• Amphotericin B (administration & dosage)
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Antifungal Agents (administration & dosage)
• Candidiasis (drug therapy)
• Child
• Drug Therapy, Combination
• HSP90 Heat-Shock Proteins (antagonists & inhibitors)
• Humans
• Lymphoma, Non-Hodgkin (complications, drug therapy)
• Male
• Peritonitis (drug therapy)